U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
The Parent Company was added by ICIJ.
The parent company information is based on 2017 public records.
Biomet has initiated this action following investigation that identified two (2) specific lots of part number 42-422561 were incorrectly labeled. one (1) unit (lot 025640) was received back from distributor's office as a product complaint.
조치
The firm, BIOMET Orthopedics, sent an "URGENT MEDICAL DEVICE RECALL NOTICE" letter dated January 23, 2012 to its customers. The letter described the product, problem and actions to be taken. The customers were instructed to do the following:
-Immediately locate and remove the above identified Signature " Guide and Model Set.
-Carefully follow the instructions on the enclosed FAX Back Response Form .
- Fax a copy of the Response Form to 574-372-1683 prior to return of product.
- Use priority carrier for your shipment.
- If you have further distributed this product, you MUST notify hospital personnel of this action, via the enclosed recall letter. This letter MUST be given to hospital personnel responsible for receiving recall notices. Confirm receipt of this notice by calling, 800-348-9500, extension 3983.
Questions related to this notice should be directed to 574-372-3983, Monday through Friday, 8AM to 5PM.
REF 42-422561 SIGNATURE QTY, 1 TKA GDE/MDL (Prosthesis, knee) SET 04-05 DGHUMPHR-NOV52LKA-J_K-00432022 SLIDEX DISTAL-MP/PREMIER TIBIAL CUSTOM-MADE DEVICE || Signature Personalized Patient Care System is intended to be used as a surgical instrument to assist in the positioning of total and partial knee replacement components intra-operatively and in the guiding and marking of bone before cutting and to guide cutting, provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans.
“The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.